Holen Sie sich die Stockscreener-App
18.77
0.70%
0.13
Handel nachbörslich:
18.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TEVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$18.64
Offen:
$18.64
24-Stunden-Volumen:
4.92M
Relative Volume:
0.79
Marktkapitalisierung:
$21.11B
Einnahmen:
$16.29B
Nettoeinkommen (Verlust:
$-476.00M
KGV:
-9.385
EPS:
-2
Netto-Cashflow:
$679.00M
1W Leistung:
+1.84%
1M Leistung:
+7.32%
6M Leistung:
+34.26%
1J Leistung:
+108.79%
1-Tages-Spanne:
$18.48
$18.79
1-Wochen-Bereich:
$18.20
$18.80
52-Wochen-Spanne:
$8.545
$19.08
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) - GlobeNewswire Inc.
Where Do Analysts See Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Heading? - Stocks Register
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 5.28 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Monitoring Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insider movements - Knox Daily
Views of Wall Street’s Leading Experts on Teva- Pharmaceutical Industries Ltd. ADR - SETE News
Selling Buzz: Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial Daniell Richard sells 98,943 shares of the company – Knox Daily - Knox Daily
Qifu Technology Inc. ADR (QFIN) gets rating Initiated from Nomura - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 1.45 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Keeping an Eye on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) After Insider Trading Activity - Knox Daily
TEVA’s current quarter earnings: What analysts forecast? - US Post News
Taking a look at what insiders are doing to gauge the Teva- Pharmaceutical Industries Ltd. ADR (TEVA)’s direction - Knox Daily
HP Stock Sees Surge of Approximately 3.50% in Last Five Days - Knox Daily
RPM International, Inc. [RPM] Shares Rise 6.30 % on Wednesday - Knox Daily
Alight Inc. (ALIT) gets rating Downgrade from JP Morgan - Knox Daily
TEVA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Keycorp (NYSE: KEY) Up 50.91% This Year: What Is Going To Happen Next - Stocks Register
Argus upgrades Teva- Pharmaceutical Industries Ltd. ADR (TEVA) rating to a Buy - Knox Daily
TE Connectivity Ltd’s latest rating changes from various analysts - Knox Daily
FTCI’s latest rating updates from top analysts. - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR (TEVA): Worth A Small Bite At $17.54 - Stocks Register
How will Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) earnings compare to estimates this quarter? - US Post News
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Shares Jump Approximately 70.34% Over the Year - Knox Daily
Before You Invest, Make Sure You Check This New Oriental Education & Technology Group Inc. ADR (NYSE: EDU) Analysis – Stocks Register - Stocks Register
TEVA’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Does Walmart Inc (NYSE: WMT) Still Need To Convince Analysts? - Stocks Register
When Would Be The Best Time To Buy UiPath Inc (NYSE: PATH) Stock? - Stocks Register
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Stock trading around $17.72 per share: What’s Next? - The DBT News
Checking in on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insiders movement - Knox Daily
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY (risperidone) Extended-Release Injectable Suspension from Perseris (RBP-7000) - wallstreet:online
DLTR Shares Experience Surge in Value - Knox Daily
A company insider recently sold 708 shares of NAPCO Security Technologies Inc [NSSC]. Should You Sale? - Knox Daily
TEVA Shares Experience Surge in Value - Knox Daily
Does Teva- Pharmaceutical Industries Ltd. ADR (TEVA) offer a good opportunity for investors? - SETE News
How analysts predict Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will perform this quarter? - US Post News
Argus analysts upgrades a Buy rating for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR Inc. (TEVA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
What will the future hold for Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) stock? - US Post News
Insider Selling: Daniell Richard, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial divested 98,943 shares – Knox Daily - Knox Daily
insider CHURAY DANIEL J sale 16,975 shares of MRC Global Inc [MRC] - Knox Daily
The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Daniell Richard sells 98,943 Shares for $1.71 million - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) expanding its growth trajectory ahead - SETE News
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):